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Abstract
Congenital cytomegalovirus (CMV) remains a leading cause of disability in
children. Understanding the pathogenesis of infection from the mother via the
placenta to the neonate is crucial if we are to produce new interventions and
provide supportive mechanisms to improve the outcome of congenitally
infected children. In recent years, some major goals have been achieved,
including the diagnosis of primary maternal CMV infection in pregnant women
by using the anti-CMV IgG avidity test and the diagnosis and prognosis of foetal
CMV infection by using polymerase chain reaction real-time tests to detect and
quantify the virus in amniotic fluid. This review summarises recent advances in
our understanding and highlights where challenges remain, especially in
vaccine development and anti-viral therapy of the pregnant woman and the
neonate. Currently, no therapeutic options during pregnancy are available
except those undergoing clinical trials, whereas valganciclovir treatment is
recommended for congenitally infected neonates with moderately to severely
symptomatic disease.
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Introduction
Cytomegalovirus (CMV) remains a major cause of congenital 
infection and disease during pregnancy around the world1. Our 
understanding of the pathogenesis of CMV during pregnancy 
continues to improve through the application of new technologies 
and interventional studies. However, there remain a number of 
outstanding questions relating to CMV infection in pregnancy, 
especially in the context of women who are already seropositive 
for CMV where multiple strains may be present in the face of a 
strong T- and B-cell immune response, the comparative patho-
genesis in developed and developing countries, and the optimal 
therapeutic strategies to be deployed. Recently, there has been 
significant interest in establishing associations between genetic 
variants and strain pathogenicity of CMV. In 2013, Renzette 
et al. created the most detailed map of human CMV in vivo 
evolution to date and demonstrated that viral populations can be 
stable or rapidly differentiate, depending on the host environment2. 
Furthermore, in 2015, Sijmons et al. provided an important 
compendium of data concerning human CMV strain diversity3. 
These studies support the hypothesis that human CMV strains 
may vary in virulence, tropism, and pathogenic potential, which in 
turn is probably related to the genetic variability exhibited in key 
genes important for pathogenesis among wild-type CMV strains. 
Identification of specific, more highly pathogenic, CMV variants 
could provide clinically useful information3.
The present article will survey the progress that has been made in 
these areas, particularly over the last 4 years, and provide a suc-
cinct update on how our understanding of CMV in pregnancy has 
matured in recent years and the potentially beneficial effects of anti-
viral therapy in managing congenital CMV infection and disease.
Cytomegalovirus in pregnancy: risk factors and 
epidemiology
CMV seroprevalence across the globe varies substantially both 
between and within countries4–7 (Figure 1). As a rule of thumb, 
lower socioeconomic groups have a higher incidence of CMV expo-
sure and resource-poor countries also have higher seroprevalence 
levels with infection (from 84% to 100% IgG-positive) frequently 
acquired early in life8. These epidemiological patterns have a direct 
impact on the incidence of congenital infection and disease. For 
example, the classic high-risk setting for congenital CMV infection 
and particularly disease is where a seronegative mother becomes 
infected during pregnancy (in particular, during the first trimester) 
and transmits the virus to the foetus. In this situation, transmission 
to the foetus occurs in 30–35% of cases and congenital disease 
in around 10–15% of those born with congenital infection6. In 
contrast, in women who are already seropositive, reactivation 
or reinfection gives rise to a foetal infection rate of about 1.2%, 
which whilst much lower than primary infection acts to be the 
main contributor to the total number of congenital infections (and 
disease) worldwide9–11. Lastly, increasing observations demonstrate 
the risk for symptomatic infection at birth, and sequelae, especially 
hearing loss, are similar upon primary and non-primary maternal 
CMV infection8,12–15.
In terms of pathogenesis, in children with symptomatic disease, 
approximately 4% will die in utero or shortly after birth and this is 
usually because of significant neurological damage and multi-organ 
failure16. Of the remainder, about 60% will have cognitive defects; 
sensorineural hearing loss (SNHL) and neurological impair-
ment are two common manifestations16. Indeed, SNHL, which 
is prevalent at about 35%, is a progressive disease, and, even in 
Figure 1. Global cytomegalovirus (CMV) seroprevalence levels and incidence of congenital CMV infection. Worldwide CMV 
seroprevalence rates among women of reproductive age and birth prevalence of congenital CMV infection (reproduced from 1). CMV 
seroprevalence rates are shown in different shades of colour, and congenital CMV birth prevalence rates are shown by the circles.
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neonates born with asymptomatic infection, there is now increasing 
evidence that a significant subset of these will develop SNHL17–19. 
Thus, early identification of children at risk of progressive SNHL 
is a priority, as interventions may provide a substantial benefit 
(an aspect that will be discussed later).
In CMV seropositive women, the risk factors for congenital 
infection are less well defined, although in a recent study of preg-
nant Polish women, around 22% of seropositive women who 
transmitted to their neonate were infected with multiple CMV 
strains as judged by glycoprotein B genotyping20. Additional 
studies by targeted sequencing demonstrated that other genes of 
CMV have highly variable regions including proteins gN, gO, 
gH, and UL1442,3. However, the role that mixed genotype infec-
tion plays in transmission and the immune response against these 
different strains has not been fully investigated.
In healthy humans, the T-cell immune response against CMV is 
both multi-specific and high frequency in both CD4 and CD8 
compartments21. In many studies of transplant recipients, a high 
frequency of functional (that is, interferon gamma [IFN-γ]- 
producing) CMV-specific CD8 together with CD4 helper cells has 
been shown to be protective against high-level CMV replication 
and also disease22–25. Thus, the assumption might be that in preg-
nant women a similar T-cell phenotype may be protective against 
CMV disease. Recent data question this hypothesis; with IFN-γ 
ELISpot assay and CMV IgG avidity testing, it was shown that 
women who transmitted to their offspring were more likely to 
have a higher T-cell response and that the combination of low 
CMV IgG avidity and high ELISpot values gave an area under the 
curve of 0.8726.
Eldar-Yedidia et al. proposed a novel normalisation method 
testing the individual IFN-γ response to CMV (IFN-γ relative 
response, or RR) detected by the QuantiFERON assay and found 
that the group of women with a low CMV IFN-γ RR did not 
transmit the virus to the foetus27. However, Forner et al. showed 
that the results of CMV cell-mediated immunity obtained with 
the ELISpot assay were more significantly associated with the 
risk of CMV transmission compared with those obtained with 
the QuantiFERON test28. Further studies in a larger number of 
CMV-infected pregnant women should be performed in order 
to verify the prognostic efficacy of determining the maternal 
CMV-specific T-cell immune response. Finally, data using a 
Rhesus animal model of CMV have clearly demonstrated that, in 
the absence of CD4 T cells, more severe CMV disease was 
observed in the offspring29.
Advances in screening for cytomegalovirus in 
pregnancy
Screening of mothers for CMV IgG on a routine basis has not 
been universally adopted, although at present eight European 
countries have adopted a de facto screening30,31. One of the stated 
reasons why such an approach is not warranted is the incidence of 
congenital infection and disease amongst children born to women 
who are already CMV IgG positive. However, if there is clinical 
suspicion of primary CMV infection, appropriate testing of ante-
natal samples for seroconversion and investigating IgG avidity 
levels are standard practice32. To assess the risk of transmission 
to the foetus, prenatal testing of amniotic fluid at 20–21 weeks of 
gestation by real-time polymerase chain reaction (PCR) has also 
been investigated33–40. The foetal CMV diagnosis is reliable: a 
negative result in the amniotic fluid can rule out foetal infection 
with a high degree of certainty. Positive results in amniotic fluid 
identify CMV-infected foetuses but do not discriminate those 
infants who will have symptoms at birth. Studies have shown that 
low viral loads in amniotic fluid are associated with a lower risk 
of congenital disease, but it is clear that the positive and negative 
predictive values of qualitative and quantitative PCR on amni-
otic fluid are not sufficiently robust for routine deployment and 
should be considered with caution41,42.
Advances in understanding the role of the placenta 
in infection
In recent years, our understanding of the complex interaction 
between the placenta and CMV and how it relates to congenital 
infection has improved significantly. Of particular note here is 
the work of the Pereira group. The recent observations show that 
CMV particularly infects amniotic membranes43, impairs cytotro-
phoblast-induced lymphangiogenesis and vascular remodelling 
in the placenta, and arrests the correct development of human 
trophoblast progenitor cells, thus interfering with the earliest 
stages in the growth of new villi. This results in increased hypoxia, 
which ultimately contributes to restriction in foetal growth44. 
In fact, immunohistochemical and virological studies of placental 
tissues suggested that severe placental infection was associated 
with diffuse villitis and necrosis, consistent with functional 
impairment and possible consequent hypoxic cerebral damage45.
CMV infection also appears to persist in the amniotic epithelial 
cells and has been associated with increased expression of the 
anti-apoptotic proteins survivin and Bclx-l through both STAT-3-
dependent and -independent mechanisms.46. In addition, CMV has 
been shown to inhibit Wnt5a-stimulated migration of trophoblasts 
through increasing the expression of the WNT receptor ROR247.
CMV infection induces an innate immune response in the pla-
centa, significantly altering the decidual cytokine and chemok-
ine environment. In particular, Hamilton et al. highlighted how 
CMV infection modulates the placental immune environment, 
suggesting CMV-induced upregulation of monocyte chemoattract-
ant protein-1 (MCP-1) and tumour necrosis factor-alpha (TNF-α) 
expression as a potential initiator or exacerbator (or both) of 
placental and foetal injury48. In CMV-infected decidual cultures, 
there is a predominant induction of INF-γ and inducible protein 1 
(IP-1) expression, reflecting the immune activation generated upon 
CMV infection49.
Advances in risk stratification of infected neonates
A comprehensive analysis by Cannon et al.50 assessed each of 
the sequelae of congenital CMV and the evidence for different 
interventions making a positive impact. This study concluded that 
there was good evidence that non-pharmaceutical interventions 
for children with delayed hearing loss by 9 months of age would 
have an impact and that a moderate effect of pharmaceutical 
interventions would be observed on hearing loss between 9 and 
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24 months and on CMV-related cognitive deficits. However, the 
evidence for interventions affecting children with hearing loss of 
neurological impairment occurring after 24 months was weak. On 
this basis, the authors proposed that a combination of newborn 
screening and early detection and interventions would benefit thou-
sands of children with congenital CMV in the USA alone.
At present, no European country routinely screens for congenital 
CMV infection. In four states in the USA, the efforts of non-profit 
organisations have determined the introduction and passage of leg-
islation for infant CMV screening. Attention over the last decade 
has turned to the use of dried blood spots, since these are rou-
tinely taken to diagnose biochemical and genetic disorders in the 
newborn. However, the sensitivity of this approach using PCR-
based detection methods is highly variable (28–100%), even when 
large sample sizes have been used51–53. Further improvements in 
sensitivity can be achieved by standardised procedures of viral 
DNA extraction and nested PCR approaches, with a recent article 
showing a sensitivity of 81%54. As an alternative, saliva has 
been suggested as the sample of choice, but this would require a 
different sample to be taken at birth, and for routine screening this 
may prove to be too complex and costly to adopt55.
Impact of co-infections on cytomegalovirus in 
pregnancy
A major co-infection which impacts directly on CMV in pregnancy 
is HIV infection. Recent data highlight that HIV-1/CMV co-infected 
infants have a high risk of mortality, neurological defects, and HIV 
disease progression56,57. Rates of congenital CMV infection in HIV-
exposed but uninfected infants in Nairobi have been shown to be 
6.3% and this increased to 29% if the infant was HIV infected58. To 
date, no large systematic studies have investigated the transmission 
frequency in HIV-infected women of CMV to the neonate in the 
context of both maternal CMV infection during pregnancy versus 
post-partum infection, which is known to be prominent through 
CMV in breast milk. However, one study has used data from a 
valacyclovir interventional study (for herpes simplex virus [HSV] 
infection) to investigate its effects on infant CMV acquisition59. 
Valacyclovir at the doses used for HSV-1 control has a relatively 
weak anti-viral effect on CMV replication. The upshot of this study 
was that maternal valacyclovir use had no effect on the timing or 
acquisition of infant CMV or on breast milk viral loads but that it 
did reduce cervical CMV shedding. Further studies using high-dose 
valacyclovir or safer anti-CMV drugs would be warranted in this 
patient group60. It has also been shown that maternal highly active 
anti-retroviral therapy (HAART) can reduce vertical transmission 
of CMV but does not reduce breast milk levels and so would be 
unlikely to impact on post-natal infection61.
Advances in anti-viral therapy
The most extensive study to date on the use of anti-viral therapy 
for symptomatic CMV disease was published in 201562. The 
study enrolled 96 neonates who were randomly assigned to either 
6 months or 6 weeks of valganciclovir therapy. The primary 
endpoint (best ear audiological improvement) was similar between 
the two arms, although total ear hearing was more likely to have 
improved and be stable at 12 months in the 6-month valganciclovir 
arm. Interestingly, the 6-month treatment arm was also associated 
with significant improvements (P <0.004) in neurodevelopmental 
scores (improvement in the language-composite component and 
the receptive-communication scale). This study builds on a 
previous anti-viral study of intravenous ganciclovir63 and, though 
encouraging, shows that until we have access to anti-CMV drugs 
with greater potency and improved side-effect profiles, it is unlikely 
that this area will move forward rapidly. Currently, valganciclovir 
treatment for 6 months is recommended for congenitally infected 
neonates with moderate to severe CMV disease and should be 
started within the first month of life.
At present, there is no evidence for the potential benefit of treat-
ment of asymptomatic infants or asymptomatically infected chil-
dren with isolated sensorineural hearing loss (≥20 dB in one or both 
ears)62,64. One non-randomised, single-blind clinical trial is cur-
rently investigating whether early treatment with valganciclovir of 
infants up to 12 weeks of age with both congenital CMV infection 
and SNHL can prevent progression of hearing loss (ClinicalTrials.
gov identifier NCT02005822). Two other clinical trials are being 
undertaken in order to provide evidence for treatment options in 
congenitally CMV-infected newborns (ClinicalTrials.gov identifi-
ers NCT01649869 and NCT02606266).
A preliminary report on an open-label phase II study of in utero 
treatment of congenital CMV with high-dose valacyclovir (8 g/day) 
has recently been published. The interim analysis indicates that 
longer-term exposure to valacyclovir (median of 89 days) decreases 
foetal viral loads significantly and combined with historical con-
trols decreases the proportion of symptomatic neonates from 57% 
to 18%60. However, the trial design using historical controls is not 
optimal and so further, more substantial analysis of this ongoing 
study is required and there is a need for others to replicate the study 
design in a controlled way.
Vaccine development and its potential impact
The basic reproductive number (Ro) for CMV for infections occur-
ring in the developed world is around 2.4, meaning that for herd 
immunity a vaccine update rate (assuming 100% efficacy) would 
need to be 59–62% to achieve eradication65. Modelling has shown 
that if vaccination was started in all toddlers and children aged 12, 
after 4 years a decline in infected babies occurs (owing to girls 
immunised at age 12 starting to enter child-bearing age) but that 
a more rapid decline is observed for babies with congenital infec-
tion born to seronegative women and also seropositive women who 
become re-infected during pregnancy66. To date, only a recom-
binant CMV glycoprotein B (gB) vaccine administered with the 
adjuvant MF59 has been evaluated in seronegative women; the vac-
cine showed an approximately 50% reduction in maternal infection 
in women vaccinated67. This phase 2 study also observed one con-
genital infection in the vaccine group compared with three in the 
placebo arm, although the sample size prevented statistically valid 
analysis of this observation.
Very recently, a study performed in a guinea pig model demon-
strated that immunisation with a novel bivalent vaccine based on 
a non-replicating lymphocytic choriomeningitis virus (LCMV) 
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vector expressing gB and pp65 did not show interference. More-
over, the bivalent vaccine elicited potent humoral and cellular 
responses and conferred protection, reducing the magnitude of 
maternal viremia and improving pup outcomes. These results sup-
port further testing of LCMV-vector-based human CMV vaccines 
in clinical trials68.
An alternative approach using hyperimmune globulin to prevent 
congenital CMV has also been subjected to a randomised control-
led trial69. In this study, 124 pregnant women with primary CMV 
infection at 5–26 weeks of gestation were randomly assigned to 
hyperimmune globulin or placebo every 4 weeks until 36 weeks 
of gestation or until CMV was detected in amniotic fluid. The rate 
of congenital infection was comparable between the two groups 
(hyperimmune globulin 33%, placebo 44%; P = 0.13). Hyperim-
mune globulin had no effect on maternal CMV DNA levels in the 
blood or in time to clearance of DNA from the blood and did not 
impact on CMV DNA levels in the placenta. However, the results 
of this randomised placebo-controlled trial showed no agreement 
with those from a non-randomised study published in 2005 by 
Nigro et al., who showed that the administration of CMV-specific 
hyperimmune globulin to pregnant women with primary infection 
significantly decreased the rate of mother-to-foetus transmission, 
from 40% to 16% (P = 0.04)70. Further studies are needed given the 
biological plausibility of this approach70.
Currently, two randomised, phase 3 studies of the prevention of 
congenital infection are underway. One, sponsored by Biotest, 
is being conducted in Europe, and the second, sponsored by the 
Eunice Kennedy Shriver National Institute of Child Health and 
Human Development, is ongoing in the USA (ClinicalTrials.gov 
identifier NCT01376778).
The hope is that these studies will further aid our understanding of 
the efficacy and safety of hyperimmune globulin administration as 
a means of preventing congenital CMV infection.
A systematic review published by Hamilton et al. highlighted how, 
despite a number of case series and case control and observational 
studies, there is a significant lack of robust clinical trial data exam-
ining prophylactic interventions for congenital CMV infection71.
Conclusions and future prospects
The last few years have seen real progress in understanding the 
basic biology of CMV in the placenta and the role that ongoing 
viral replication plays in the pathogenesis of CMV disease in the 
neonate. However, for a variety of reasons, screening of pregnant 
women for CMV, whilst supported, has not been implemented glo-
bally, and routine surveillance of neonates for evidence of CMV 
infection requires new methodologies or improvement of the cur-
rent ones, especially with respect to simpler protocols and lower 
costs. The therapy of the newborn infant with CMV shows prom-
ise, but we need safer and preferably more potent drugs to make 
a large impact; new drugs such as letermovir are on the horizon, 
as are active vaccine development programmes, making the future 
of CMV in pregnancy a very active area of basic and translational 
research.
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